CSS
TVTX icon

Cubist Systematic Strategies’s Travere Therapeutics TVTX Stock Holding History

Cubist Systematic Strategies’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-699,182
Closed -$10.3M – 3579
2025
Q2 		$10.3M Buy
+699,182
New +$11.6M 0.05% 580
2024
Q4 		– Sell
-103,933
Closed -$1.45M – 3578
2024
Q3 		$1.45M Sell
103,933
-242,135
-70% -$2.52M 0.01% 1597
2024
Q2 		$2.84M Sell
346,068
-2,062
-0.6% -$13.9K 0.02% 1111
2024
Q1 		$2.68M Buy
348,130
+127,485
+58% +$1.08M 0.02% 1415
2023
Q4 		$1.98M Sell
220,645
-112,208
-34% -$817K 0.01% 1518
2023
Q3 		$2.98M Buy
332,853
+128,071
+63% +$1.81M 0.02% 1089
2023
Q2 		$3.15M Buy
204,782
+167,106
+444% +$3.04M 0.02% 1140
2023
Q1 		$847K Buy
+37,676
New +$801K 0.01% 2302
2022
Q4 		– Sell
-341
Closed -$8K – 4605
2022
Q3 		$8K Sell
341
-17,047
-98% -$440K ﹤0.01% 4300
2022
Q2 		$421K Sell
17,388
-50,729
-74% -$1.28M ﹤0.01% 3186
2022
Q1 		$1.75M Sell
68,117
-4,431
-6% -$118K 0.01% 1590
2021
Q4 		$2.25M Buy
72,548
+31,616
+77% +$890K 0.02% 1259
2021
Q3 		$993K Sell
40,932
-69,643
-63% -$1.28M 0.01% 1536
2021
Q2 		$1.61M Buy
110,575
+90,686
+456% +$1.79M 0.02% 1244
2021
Q1 		$497K Sell
19,889
-19,272
-49% -$532K 0.01% 1959
2020
Q4 		$1.07M Buy
39,161
+7,645
+24% +$178K 0.01% 1339
2020
Q3 		$582K Sell
31,516
-17,882
-36% -$348K 0.01% 1660
2020
Q2 		$1.01M Buy
49,398
+45,197
+1,076% +$720K 0.02% 1171
2020
Q1 		$61K Sell
4,201
-12,023
-74% -$181K ﹤0.01% 1984
2019
Q4 		$230K Sell
16,224
-34,746
-68% -$444K ﹤0.01% 1981
2019
Q3 		$591K Buy
50,970
+19,399
+61% +$321K 0.01% 1214
2019
Q2 		$634K Sell
31,571
-19,667
-38% -$388K 0.01% 1324
2019
Q1 		$1.16M Buy
51,238
+10,110
+25% +$223K 0.04% 682
2018
Q4 		$931K Buy
41,128
+40,757
+10,986% +$1.01M 0.04% 594
2018
Q3 		$11K Sell
371
-24,829
-99% -$710K ﹤0.01% 1815
2018
Q2 		$687K Buy
25,200
+19,171
+318% +$511K 0.03% 647
2018
Q1 		$135K Sell
6,029
-7,972
-57% -$190K 0.01% 1531
2017
Q4 		$295K Buy
14,001
+11,007
+368% +$252K 0.02% 1256
2017
Q3 		$75K Buy
2,994
+1,308
+78% +$28.8K ﹤0.01% 1680
2017
Q2 		$33K Sell
1,686
-1,030
-38% -$18.7K ﹤0.01% 1582
2017
Q1 		$50K Buy
2,716
+926
+52% +$18.1K ﹤0.01% 1476
2016
Q4 		$34K Buy
1,790
+922
+106% +$18.9K ﹤0.01% 1609
2016
Q3 		$19K Buy
+868
New +$16.5K ﹤0.01% 1619
2015
Q4 		– Sell
-3,590
Closed -$73K – 1950
2015
Q3 		$73K Buy
3,590
+671
+23% +$19.9K ﹤0.01% 1683
2015
Q2 		$97K Sell
2,919
-18,147
-86% -$497K ﹤0.01% 1622
2015
Q1 		$505K Sell
21,066
-15,696
-43% -$239K 0.02% 930
2014
Q4 		$450K Buy
+36,762
New +$380K 0.02% 933
2014
Q3 		– Sell
-2,081
Closed -$24K – 1883
2014
Q2 		$24K Buy
+2,081
New +$28.2K ﹤0.01% 1454

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Cubist Systematic Strategies's TVTX Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Travere Therapeutics (TVTX) in Q3 2025, closing a stake of 699,182 shares — an estimated $10.3M sold.

Cubist Systematic Strategies first reported a position in TVTX in Q2 2014 and held it in 38 quarters. The position peaked at $10.3M in Q2 2025. 238 funds tracked by Wall St. Rank hold TVTX as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining Travere Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 699,182 Travere Therapeutics shares in Q3 2025, an estimated $10.3M.
  • Cubist Systematic Strategies first reported a position in Travere Therapeutics in Q2 2014 and held it in 38 quarters.
  • Cubist Systematic Strategies's Travere Therapeutics position peaked at $10.3M in Q2 2025.
  • 238 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.